Avilar Therapeutics

About

Avilar Therapeutics is a biopharmaceutical company based in Waltham, MA, focused on the discovery and development of extracellular protein degraders. Founded with support from RA Capital Management, Avilar aims to address diseases linked to extracellular and membrane-bound proteins, which represent a significant portion of human proteins and are involved in various health conditions. The company's proprietary technology, known as ATACs (ASGPR Targeting Chimeras), consists of bifunctional molecules that target and degrade disease-causing extracellular proteins. This process utilizes the asialoglycoprotein receptor (ASGPR) to shuttle proteins to hepatocytes, where they are broken down in the endolysosome. Avilar's platform features high-affinity ligands, advanced modeling tools, and a modular design that allows for rapid development of degraders targeting a wide range of extracellular proteins. Avilar is advancing a broad pipeline of first-in-class degraders and has secured $75 million in funding to support its research and development efforts. The company is dedicated to pioneering new therapeutic approaches and fostering a collaborative culture that values diverse perspectives.